have a certain type of heart disease or take certain medications.
•Drinking alcohol during treatment with POTIGA may increase the side effects that you get with POTIGA.
The most common side effects of POTIGA include:
•dizziness
•somnolence
•sleepiness
•tiredness
•confusion
•spinning sensation (vertigo)
•tremor
•problems with balance and muscle coordination, including trouble with walking and moving
•blurred or double vision
•trouble concentrating
•memory problems
•weakness
Tell your healthcare provider about any side effect that bothers you or that does not go away.
These are not all the possible side effects of POTIGA. Ask your healthcare provider or pharmacist for more information.
Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
How should I store POTIGA?
•Store POTIGA at room temperature at 59°F to 86°F (15°C to 30°C).
•Keep POTIGA and all medicines out of the reach of children.
General information about the safe and effective use of POTIGA.
Medicines are sometimes prescribed for purposes other than those listed in a Medication Guide. Do not use POTIGA for a condition for which it was not prescribed. Do not give POTIGA to other people, even if they have the same symptoms you have. It may harm them.
This Medication Guide summarizes the most important information about POTIGA. If you would like more information, talk with your healthcare provider. You can ask your healthcare provider or pharmacist for information about POTIGA that is written for healthcare professionals.
For more information, go to www.potiga.com or call 1-888-825-5249.
What are the ingredients in POTIGA?
Active ingredient: ezogabine.
Inactive ingredients in all strengths: croscarmellose sodium, hypromellose, lecithin, magnesium stearate, microcrystalline cellulose, polyvinyl alcohol, talc, titanium dioxide, and xanthan gum.
50-mg and 400-mg tablets also contain: carmine.
50-mg, 300-mg, and 400-mg tablets also contain: FD&C Blue No 2.
200-mg and 300-mg tablets also contain: iron oxide yellow.
POTIGA is a trademark of Valeant Pharmaceuticals North America.
The brands listed are trademarks of their respective owners and are not trademarks of GlaxoSmithKline. The makers of these brands are not affiliated with and do not endorse GlaxoSmithKline or its products.
GlaxoSmithKline
Research Triangle Park, NC 27709
This Medication Guide has been approved by the U.S. Food and Drug Administration.
©2012, GlaxoSmithKline. All rights reserved.
March 2012
PTG:4MG
Principal Display Panel
NDC 0173-0810-59
Potiga™
(ezogabine) Tablets
50 mg
Rx only
CV
90 Tablets
Dispense the accompanying Medication Guide to each patient.
Store at 25°C (77°F); excursions permitted between 15°-30°C (59°-86°F). [See USP Controlled Room Temperature.]
Do not use if printed safety seal under cap is broken or missing.
Each tablet contains 50 mg ezogabine.
See prescribing information for dosage information.
POTIGA is a trademark of Valeant Pharmaceuticals North America.
GlaxoSmithKline, Research Triangle Park, NC 27709
Rev. 3/12
A081776
Principal Display Panel
NDC 0173-0812-59
Potiga™
(ezogabine) Tablets
200 mg
Rx only
CV
90 Tablets
Dispense the accompanying Medicatio |
